Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial


Por: Ciruelos E, Villagrasa P, Pascual T, Oliveira M, Pernas S, Pare L, Escriva-de-Romani S, Manso L, Adamo B, Martinez E, Cortes J, Vazquez S, Perello A, Garau I, Mele M, Martinez N, Montano A, Bermejo B, Morales S, Echarri M, Vega E, Gonzalez-Farre B, Martinez D, Galvan P, Canes J, Nuciforo P, Gonzalez X, Prat A

Publicada: 15 nov 2020
Resumen:
Purpose: To assess palbociclib in combination with trastuzumab with or without endocrine therapy in patients with HER2-positive advanced breast cancer. Patients and Methods: PATRICIA is a prospective, open-label, multicenter phase II trial. Patients had received 2-4 prior lines of anti-HER2-based regimens. Treatment consisted of palbociclib 200 mg daily for 2 weeks and 1 week off plus trastuzumab. The study was based on a Simon two-stage design comprising three cohorts: estrogen receptor (ER)-negative (cohort A), ER-positive (cohort B1), and ER-positive with letrozole (cohort B2). ER-positive patients were randomized to cohorts B1 or B2. Primary endpoint was progression-free survival rate at 6 months (PFS6). Secondary objectives included safety and evaluation of the PAM50 intrinsic subtypes. Results: Seventy-one patients were recruited (n = 15 in cohort A and 28 in each cohort B). The PFS6 rate in cohorts A, B1, and B2 was 33.3% (5/15), 42.8% (12/28), and 46.4% (13/28), respectively. Regarding safety, grade 1-2 and 3-4 toxicities occurred in 97.7% and 84.4% of patients, respectively. The most common grade 3-4 toxicities were neutropenia (66.4%) and thrombocytopenia ( 11.3%). Regarding PAM50, 59 (83.1%) tumors were profiled. Luminal disease defined by PAM50 was found independently associated with longer PFS compared with non-luminal disease (10.6 vs. 4.2 months median PFS; adjusted hazard ratio = 0.40; P = 0.003). Conclusions: Palbociclib in combination with trastuzumab is safe and exhibits promising survival outcomes in trastuzumab pretreated ER-positive/HER2-positive advanced breast cancer with a PAM50 Luminal A or B subtype. The enrollment was stopped prematurely, and a new randomized cohort was opened in this population.

Filiaciones:
Ciruelos E:
 Hosp Univ 12 Octubre, Ave Cordoba S-N, Madrid 28041, Spain

 Ctr Integral Oncol Clara Campal HM CIOCC, Madrid, Spain

 SOLTI Breast Canc Res Grp, Barcelona, Spain

Villagrasa P:
 SOLTI Breast Canc Res Grp, Barcelona, Spain

Pascual T:
 SOLTI Breast Canc Res Grp, Barcelona, Spain

 Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain

 Hosp Clin Barcelona, Barcelona, Spain

 Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA

Oliveira M:
 SOLTI Breast Canc Res Grp, Barcelona, Spain

 Vall dHebron Univ Hosp, Barcelona, Spain

 Vall dHebron Inst Oncol VHIO, Barcelona, Spain

Pernas S:
 SOLTI Breast Canc Res Grp, Barcelona, Spain

 Inst Catala Oncol, Lhospitalet De Llobregat, Spain

Pare L:
 SOLTI Breast Canc Res Grp, Barcelona, Spain

 Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain

Escriva-de-Romani S:
 Vall dHebron Univ Hosp, Barcelona, Spain

Manso L:
 Hosp Univ 12 Octubre, Ave Cordoba S-N, Madrid 28041, Spain

Adamo B:
 Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain

 Hosp Clin Barcelona, Barcelona, Spain

Martinez E:
 Consorcio Hosp Prov Castellon, Castellon de La Plana, Spain

Cortes J:
 IOB Inst Oncol, Quiron Grp, Madrid, Spain

 IOB Inst Oncol, Quiron Grp, Barcelona, Spain

Vazquez S:
 Inst Catala Oncol, Lhospitalet De Llobregat, Spain

Perello A:
 Hosp Univ Son Espases, Palma De Mallorca, Spain

Garau I:
 Hosp Son Llatzer, Palma De Mallorca, Spain

Mele M:
 Hosp Univ St Joan de Reus, Reus, Spain

Martinez N:
 Hosp Univ Ramon y Cajal, Madrid, Spain

Montano A:
 Hosp Univ Virgen del Rocio, Seville, Spain

Bermejo B:
 Hosp Clin Univ Valencia, Valencia, Spain

Morales S:
 Hosp Univ Arnau de Vilanova Lleida, Lleida, Spain

Echarri M:
 Hosp Univ Severo Ochoa, Madrid, Spain

Vega E:
 Ctr Integral Oncol Clara Campal HM CIOCC, Madrid, Spain

Gonzalez-Farre B:
 Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain

 Hosp Clin Barcelona, Barcelona, Spain

Martinez D:
 Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain

Galvan P:
 Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain

Canes J:
 SOLTI Breast Canc Res Grp, Barcelona, Spain

Nuciforo P:
 Vall dHebron Univ Hosp, Barcelona, Spain

 Vall dHebron Inst Oncol VHIO, Barcelona, Spain

Gonzalez X:
 SOLTI Breast Canc Res Grp, Barcelona, Spain

 Inst Oncol Dr Rosell, Barcelona, Spain

 Hosp Gen Cataluna, Sant Cugat Del Valles, Spain

Prat A:
 SOLTI Breast Canc Res Grp, Barcelona, Spain

 Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain

 Hosp Clin Barcelona, Barcelona, Spain
ISSN: 10780432





CLINICAL CANCER RESEARCH
Editorial
American Association for Cancer Research, 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA, Estados Unidos America
Tipo de documento: Article
Volumen: 26 Número: 22
Páginas: 5820-5829
WOS Id: 000592798200008
ID de PubMed: 32938620

MÉTRICAS